Recurrent Breast Carcinoma Clinical Trials

9 recruiting

Recurrent Breast Carcinoma Trials at a Glance

9 actively recruiting trials for recurrent breast carcinoma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Rochester, San Francisco, and Atlanta. Lead sponsors running recurrent breast carcinoma studies include Mayo Clinic, Laura Huppert, MD, BA, and Emory University.

Browse recurrent breast carcinoma trials by phase

Treatments under study

About Recurrent Breast Carcinoma Clinical Trials

Looking for clinical trials for Recurrent Breast Carcinoma? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Breast Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Breast Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Not Applicable

Study on Recurrent Breast Cancer and Repeated Radiation Therapy

Recurrent Breast Carcinoma
Turku University Hospital60 enrolled2 locationsNCT06704659
Recruiting

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma
Mayo Clinic2,000 enrolled1 locationNCT06217874
Recruiting
Phase 1

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+24 more
Emory University18 enrolled4 locationsNCT06324240
Recruiting
Phase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaInvasive Breast Carcinoma+2 more
Mayo Clinic54 enrolled1 locationNCT04521764
Recruiting
Phase 3

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7Cardiotoxicity+2 more
SWOG Cancer Research Network491 enrolled590 locationsNCT03418961
Recruiting
Phase 2

Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial

Recurrent Breast CarcinomaIpsilateral Recurrence
Amsterdam UMC, location VUmc25 enrolled1 locationNCT06640881
Recruiting
Phase 2

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Stage III Breast CancerTriple-Negative Breast CarcinomaRecurrent Breast Carcinoma+6 more
Laura Huppert, MD, BA150 enrolled12 locationsNCT03971409
Recruiting
Phase 2

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Triple-Negative Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer+4 more
Northwestern University100 enrolled1 locationNCT03213041